Copytele Inc Share Price OTC Bulletin Board
Equities
COPY
US2177211099
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
06-24 | Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study | MT |
06-24 | Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 70.73M 5.59B |
---|---|---|---|---|---|
Net income 2024 * | -13M -1.03B | Net income 2025 * | -15M -1.19B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.14
x | P/E ratio 2025 * |
-4.91
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.95% |
Latest transcript on Copytele Inc
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 31/10/12 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 31/10/16 |
Pamela Garzone
PRN | Corporate Officer/Principal | 70 | 06/09/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 30/06/99 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 31/10/12 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 22/10/19 |
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- ANIX Stock
- COPY Stock